Bioreactor-based roadmap for the translation of tissue engineering strategies into clinical products
How can automated bioreactor technology accelerate the commercialization of cell and tissue therapy products for regenerative medicine?
This scientific article co-authored by Octane CEO Tim Smith lays out a roadmap highlighting why and how bioreactors must be implemented throughout the development of engineered tissue products, allowing scientific, medical, industrial and regulatory parties to address basic research questions and conduct sound preclinical studies, ultimately facilitating effective commercialization of engineered clinical products.
Trends in Biotechnology, Volume 27, Issue 9, 2009, ISSN 0167-7799
Authors: Ivan Martin, Timothy Smith and David Wendt
This innovation has been translated into clinical use on a global scale through a partnership between Octane Orthobiologics and Aesculap Biologics.